XL01126
degrades LRRK2 in human peripheral blood mononuclear cells
(PBMCs) derived from healthy donors and mouse bone marrow-derived
macrophages (BMDMs). Representative Western blotting of total LRRK2,
LRRK2-pSer935, pRab10, Rab10 total, and GAPDH levels following treating
the PBMCs with XL01126 and cis-XL01126 at the indicated
concentrations for 4 h (A) and 24 h (B). The relative LRRK2 protein
and pRab10 levels were obtained by quantifying the ratios of total
LRRK2/GAPDH or Rab10-pThr73/total Rab10, respectively, and the ratios
were normalized to the DMSO-treated samples. The relative LRRK2 and
pRab10 protein levels were plotted against the compound concentration
and fitted against “nonlinear regression, one site-fit log IC50” in GraphPad to obtain the DC50 and EC50 values. Data points are presented as mean ± standard
error of the mean (SEM) from three biological independent replicates.
(C) Representative Western blotting of total LRRK2, LRRK2-pSer935,
pRab10, Rab10 total, and GAPDH levels following treating the PBMCs
with 300 nM of XL01126 and cis-XL01126 for the indicated
time periods. The relative LRRK2 protein and pRab10 levels were obtained
by quantifying the ratios of total LRRK2/ GAPDH or Rab10-pThr73/total
Rab10, respectively, and the ratios were normalized to the DMSO-treated
samples. The relative LRRK2 and pRab10 protein levels were plotted
against the treatment time and were fitted against “nonlinear
regression, one-phase decay” in GraphPad to obtain the half-life
(T1/2) values. Data points are presented
as mean ± SEM from three biological independent replicates. (D)
Representative Western blotting of LRRK2 total and tubulin levels
after treating BMDMs with XL01126 and cis-XL01126
for 4 h. The relative LRRK2 levels were obtained by quantifying the
ratios of total LRRK2/tubulin and normalized to the DMSO-treated samples.
The relative LRRK2 levels were plotted against the compound concentration
and fitted against “nonlinear regression, one site-fit log IC50” in GraphPad to obtain the DC50 values.